Skip to main content
SpringerLink
Log in

Current Status of Stem Cell Treatment for Type I Diabetes Mellitus

  • Review Article
  • Published:
Tissue Engineering and Regenerative Medicine Aims and scope

Abstract

BACKGROUND:

Diabetes mellitus is a major health concern in current scenario which has been found to affect people of almost all ages. The disease has huge impact on global health; therefore, alternate methods apart from insulin injection are being explored to cure diabetes. Therefore, this review mainly focuses on the current status and therapeutic potential of stem cells mainly mesenchymal stem cells (MSCs) for Type 1 diabetes mellitus in preclinical animal models as well as humans.

METHODS:

Current treatment for Type 1 diabetes mellitus mainly includes use of insulin which has its own limitations and also the underlying mechanism of diseases is still not explored. Therefore, alternate methods to cure diabetes are being explored. Stem cells are being investigated as an alternative therapy for treatment of various diseases including diabetes. Few preclinical studies have also been conducted using undifferentiated MSCs as well as in vitro MSCs differentiated into β islet cells.

RESULTS:

These stem cell transplant studies have highlighted the benefits of MSCs, which have shown promising results. Few human trials using stem cells have also affirmed the potential of these cells in alleviating the symptoms.

CONCLUSION:

Stem cell transplantation may prove to be a safe and effective treatment for patients with Type 1 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zang L, Hao H, Liu J, Li Y, Han W, Mu Y. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:36.

    PubMed  PubMed Central  Google Scholar 

  2. IDF Diabetes Atlas, 5th edition. International Diabetes Federation. 2011. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/20:atlas-5th-edition.html.

  3. Atkinson MA, Eisenbarth GS. Type I diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–9.

    CAS  PubMed  Google Scholar 

  4. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177–266.

    Google Scholar 

  5. You WP, Henneberg M. Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ Open Diabetes Res Care. 2016;4:e000161.

    PubMed  PubMed Central  Google Scholar 

  6. Madsen OD. Stem cells and diabetes treatment. APMIS. 2005;113:858–75.

    PubMed  Google Scholar 

  7. Noguchi H. Pancreatic islet transplantation. World J Gastrointest Surg. 2009;1:16–20.

    PubMed  PubMed Central  Google Scholar 

  8. Jamiolkowski RM, Guo LY, Li YR, Shaffer SM, Naji A. Islet Transplantation in Type I Diabetes Mellitus. Yale J Biol Med. 2012;85:37–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. McCall MD, Toso C, Baetge EE, Shapiro AM. Are stem cells a cure for diabetes? Clin Sci (Lond). 2009;118:87–97.

    Google Scholar 

  10. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes. 2001;50:1691–7.

    CAS  PubMed  Google Scholar 

  11. Hori Y, Rulifson IC, Tsai BC, Heit JJ, Cahoy JD, Kim SK. Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc Natl Acad Sci U S A. 2002;99:16105–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. D’souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015;13:186.

    PubMed  PubMed Central  Google Scholar 

  13. Sheik Abdulazeez S. Diabetes treatment: a rapid review of the current and future scope of stem cell research. Saudi Pharm J. 2015;23:333–40.

    Google Scholar 

  14. Mohanty S, Jain KG, Nandy SB, Kakkar A, Kumar M, Dinda AK, et al. Iron oxide labeling does not affect differentiation potential of human bone marrow mesenchymal stem cells exhibited by their differentiation into cardiac and neuronal cells. Mol Cell Biochem. 2018. https://doi.org/10.1007/s11010-018-3309-9.

    Article  PubMed  Google Scholar 

  15. Hardikar AA, Marcus-Samuels B, Geras-Raaka E, Raaka BM, Gershengorn MC. Human pancreatic precursor cells secrete FGF2 to stimulate clustering into hormone-expressing islet-like cell aggregates. Proc Natl Acad Sci U S A. 2003;100:7117–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Gao R, Ustinov J, Pulkkinen MA, Lundin K, Korsgren O, Otonkoski T. Characterization of endocrine progenitor cells and critical factors for their differentiation in human adult pancreatic cell culture. Diabetes. 2003;52:2007–15.

    Google Scholar 

  17. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 2001;292:1389–94.

    CAS  PubMed  Google Scholar 

  18. Shiroi A, Yoshikawa M, Yokota H, Fukui H, Ishizaka S, Tatsumi K, et al. Identification of insulin-producing cells derived from embryonic stem cells by zinc-chelating dithizone. Stem Cells. 2002;20:284–92.

    CAS  PubMed  Google Scholar 

  19. Kim D, Gu Y, Ishii M, Fujimiya M, Qi M, Nakamura N, et al. In vivo functioning and transplantable mature pancreatic islet-like cell clusters differentiated from embryonic stem cell. Pancreas. 2003;27:e34–41.

    PubMed  Google Scholar 

  20. Deutsch G, Jung J, Zheng M, Lóra J, Zaret KS. A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development. 2001;128:871–81.

    CAS  PubMed  Google Scholar 

  21. Yang L, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone producing cells. Proc Natl Acad Sci U S A. 2002;99:8078–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Kodama S, Kühtreiber W, Fujimura S, Dale EA, Faustman DL. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 2003;302:1223–7.

    CAS  PubMed  Google Scholar 

  23. Vishnubalaji R, Al-Nbaheen M, Kadalmani B, Aldahmash A, Ramesh T. Skin-derived multipotent stromal cells—an archrival for mesenchymal stem cells. Cell Tissue Res. 2012;350:1–12.

    PubMed  Google Scholar 

  24. Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, Megges M, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013;9:32–43.

    CAS  PubMed  Google Scholar 

  25. Meirelles Lda S, Nardi NB. Methodology, biology and clinical applications of mesenchymal stem cells. Front Biosci (Landmark Ed). 2009;14:4281–98.

    Google Scholar 

  26. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000;109:235–42.

    CAS  PubMed  Google Scholar 

  27. Gronthos S, Brahim J, Li W, Fisher LW, Cherman N, Boyde A, et al. Stem cell properties of human dental pulp stem cells. J Dent Res. 2002;81:531–5.

    CAS  PubMed  Google Scholar 

  28. Najafzadeh N, Esmaeilzade B, Dastan Imcheh M. Hair follicle stem cells: in vitro and in vivo neural differentiation. World J Stem Cells. 2015;7:866–72.

    PubMed  PubMed Central  Google Scholar 

  29. Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int. 2012;2012:812693.

    PubMed  PubMed Central  Google Scholar 

  30. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.

    CAS  PubMed  Google Scholar 

  31. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–74.

    CAS  PubMed  Google Scholar 

  32. Horwitz EM, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10:771–4.

    CAS  PubMed  Google Scholar 

  33. Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S, et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol. 2006;111:231–9.

    PubMed  Google Scholar 

  34. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099–106.

    PubMed  Google Scholar 

  35. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant. 2008;17:1295–304.

    PubMed  Google Scholar 

  36. Kang SK, Shin MJ, Jung JS, Kim YG, Kim CH. Autologous adipose tissue-derived stromal cells for treatment of spinal cord injury. Stem Cells Dev. 2006;15:583–94.

    CAS  PubMed  Google Scholar 

  37. Cheng SK, Park EY, Pehar A, Rooney AC, Gallicano GI. Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus. Am J Stem Cells. 2016;5:74–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, et al. Comparisons of differentiation potential in human mesenchymal stem cells from Wharton’s jelly, bone marrow, and pancreatic tissues. Stem Cells Int. 2015;2015:306158.

    PubMed  PubMed Central  Google Scholar 

  39. Oh SH, Muzzonigro TM, Bae SH, LaPlante JM, Hatch HM, Petersen BE. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab Invest. 2004;84:607–17.

    CAS  PubMed  Google Scholar 

  40. Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol. 2004;10:3016–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Tang DQ, Cao LZ, Burkhardt BR, Xia CQ, Litherland SA, Atkinson MA, et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes. 2004;53:1721–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Abouzaripour M, Pasbakhsh P, Atlasi N, Shahverdi AH, Mahmoudi R, Kashani IR. In vitro differentiation of insulin secreting cells from mouse bone marrow derived stage-specific embryonic antigen 1 positive stem cells. Cell J. 2016;17:701–10.

    PubMed  PubMed Central  Google Scholar 

  43. Paz AH, Salton GD, Ayala-Lugo A, Gomes C, Terraciano P, Scalco R, et al. Betacellulin overexpression in mesenchymal stem cells induces insulin secretion in vitro and ameliorates streptozotocin-induced hyperglycemia in rats. Stem Cells Dev. 2011;20:223–32.

    CAS  PubMed  Google Scholar 

  44. Gabr MM, Sobh MM, Zakaria MM, Refaie AF, Ghoneim MA. Transplantation of insulin-producing clusters derived from adult bone marrow stem cells to treat diabetes in rats. Exp Clin Transplant. 2008;6:236–43.

    PubMed  Google Scholar 

  45. Zanini C, Bruno S, Mandili G, Baci D, Cerutti F, Cenacchi G, et al. Differentiation of mesenchymal stem cells derived from pancreatic islets and bone marrow into islet-like cell phenotype. PLoS One. 2011;6:e28175.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Gerace D, Martiniello-Wilks R, Nassif NT, Lal S, Steptoe R, Simpson AM. CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Res Ther. 2017;8:62.

    PubMed  PubMed Central  Google Scholar 

  47. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells. 2007;25:2837–44.

    CAS  PubMed  Google Scholar 

  48. Bassi ÊJ, Moraes-Vieira PM, Moreira-Sá CS, Almeida DC, Vieira LM, Cunha CS, et al. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes. 2012;61:2534–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Klinker MW, Wei CH. Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 2015;7:556–67.

    PubMed  PubMed Central  Google Scholar 

  50. Lin G, Wang G, Liu G, Yang LJ, Chang LJ, Lue TF, et al. Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells Dev. 2009;18:1399–406.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, et al. Differential expression of stem cell mobilization associated-molecules on multi lineage cells from adipose tissue and bone marrow. Immunol Lett. 2003;89:267–70.

    PubMed  Google Scholar 

  52. Timper K, Seboek D, Eberhardt M, Linscheid P, Christ-Crain M, Keller U, et al. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem Biophys Res Commun. 2006;341:1135–40.

    CAS  PubMed  Google Scholar 

  53. Dave SD, Vanikar AV, Trivedi HL. Extrinsic factors promoting in vitro differentiation of insulin-secreting cells from human adipose tissue-derived mesenchymal stem cells. Appl Biochem Biotechnol. 2013;170:962–71.

    CAS  PubMed  Google Scholar 

  54. Li J, Zhu L, Qu X, Li J, Lin R, Liao L, et al. Stepwise differentiation of human adipose-derived mesenchymal stem cells toward definitive endoderm and pancreatic progenitor cells by mimicking pancreatic development in vivo. Stem Cells Dev. 2013;22:1576–87.

    CAS  PubMed  Google Scholar 

  55. Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008;40:1135–9.

    CAS  PubMed  Google Scholar 

  56. Marappagounder D, Somasundaram I, Dorairaj S, Sankaran RJ. Differentiation of mesenchymal stem cells derived from human bone marrow and subcutaneous adipose tissue into pancreatic islet-like clusters in vitro. Cell Mol Biol Lett. 2013;18:75–88.

    CAS  PubMed  Google Scholar 

  57. Kajiyama H, Hamazaki TS, Tokuhara M, Masui S, Okabayashi K, Ohnuma K, et al. Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. Int J Dev Biol. 2010;54:699–705.

    CAS  PubMed  Google Scholar 

  58. Kadam S, Muthyala S, Nair P, Bhonde R. Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes. Rev Diabet Stud. 2010;7:168–82.

    PubMed  PubMed Central  Google Scholar 

  59. Sun NZ, Ji HS. In vitro differentiation of human placenta-derived adherent cells into insulin-producing cells. J Int Med Res. 2009;37:400–6.

    CAS  PubMed  Google Scholar 

  60. Gao F, Wu DQ, Hu YH, Jin GX, Li GD, Sun TW, et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res. 2008;151:293–302.

    CAS  PubMed  Google Scholar 

  61. Harris DT, Rogers I. Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther. 2007;2:301–9.

    CAS  PubMed  Google Scholar 

  62. Pessina A, Eletti B, Croera C, Savalli N, Diodovich C, Gribaldo L. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells. Biochem Biophys Res Commun. 2004;323:315–22.

    CAS  PubMed  Google Scholar 

  63. Sun B, Roh KH, Lee SR, Lee YS, Kang KS. Induction of human umbilical cord blood-derived stem cells with embryonic stem cell phenotypes into insulin producing islet-like structure. Biochem Biophys Res Commun. 2007;354:919–23.

    CAS  PubMed  Google Scholar 

  64. Gao F, Wu DQ, Hu YH, Jin GX. Extracellular matrix gel is necessary for in vitro cultivation of insulin producing cells from human umbilical cord blood derived mesenchymal stem cells. Chin Med J (Engl). 2008;121:811–8.

    CAS  Google Scholar 

  65. Polgár K, Adány R, Abel G, Kappelmayer J, Muszbek L, Papp Z. Characterization of rapidly adhering amniotic fluid cells by combined immunofluorescence and phagocytosis assays. Am J Hum Genet. 1989;45:786–92.

    PubMed  PubMed Central  Google Scholar 

  66. Priest RE, Marimuthu KM, Priest JH. Origin of cells in human amniotic fluid cultures: ultrastructural features. Lab Invest. 1978;39:106–9.

    CAS  PubMed  Google Scholar 

  67. Trovato L, De Fazio R, Annunziata M, Sdei S, Favaro E, Ponti R, et al. Pluripotent stem cells isolated from human amniotic fluid and differentiation into pancreatic beta-cells. J Endocrinol Invest. 2009;32:873–6.

    CAS  PubMed  Google Scholar 

  68. Ezquer F, Ezquer M, Contador D, Ricca M, Simon V, Conget P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells. 2012;30:1664–74.

    CAS  PubMed  Google Scholar 

  69. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106:419–27.

    CAS  PubMed  Google Scholar 

  70. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A. 2006;103:17438–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Bell GI, Broughton HC, Levac KD, Allan DA, Xenocostas A, Hess DA. Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem Cells Dev. 2012;21:97–109.

    CAS  PubMed  Google Scholar 

  72. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type I diabetic mice. Biol Blood Marrow Transplant. 2008;14:631–40.

    CAS  PubMed  Google Scholar 

  73. Davis NE, Hamilton D, Fontaine MJ. Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore β cell function. Curr Diab Rep. 2012;12:612–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010;59:3139–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57:1759–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19:667–79.

    PubMed  PubMed Central  Google Scholar 

  77. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64:587–92.

    CAS  PubMed  Google Scholar 

  78. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39:149–57.

    CAS  PubMed  Google Scholar 

  79. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60:347–57.

    CAS  PubMed  Google Scholar 

  80. Zhao Y. Stem cell educator therapy and induction of immune balance. Curr Diab Rep. 2012;12:517–23.

    PubMed  Google Scholar 

  81. Zhao Y, Jiang Z, Zhao T, et al. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012;10:3.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, et al. Modulation of autoimmune T-cell memory by stem cell educator therapy: phase 1/2 clinical trial. EBioMedicine. 2015;2:2024–36.

    PubMed  PubMed Central  Google Scholar 

  83. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34:747–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Chhabra P, Brayman KL. Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cells Transl Med. 2013;2:328–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Prabakar KR, Dominguez-Bendala J, Molano RD, Pileggi A, Villate S, Ricordi C, et al. Generation of glucose-sensitive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012;21:1321–39.

    PubMed  Google Scholar 

  86. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28:219–26.

    CAS  PubMed  Google Scholar 

  87. Keating A. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13:419–25.

    PubMed  Google Scholar 

  88. Prockop DJ. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther. 2007;82:241–3.

    CAS  PubMed  Google Scholar 

  89. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875–84.

    CAS  PubMed  Google Scholar 

  90. Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr Opin Oncol. 2007;19:650–5.

    PubMed  Google Scholar 

  91. Kaviani M, Negar Azarpira N. Insight into microenvironment remodeling in pancreatic endocrine tissue engineering: biological and biomaterial approaches. Tissue Eng Regen Med. 2016;13:475–84.

    CAS  Google Scholar 

  92. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36:2566–73.

    CAS  PubMed  Google Scholar 

  93. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long term benefits for myocardial repair. Circulation. 2010;122:2419–29.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the Datt Mediproducts Pvt. Ltd. for supporting their current research. We sincerely thank Dr. Rajan Datt for valuable scientific discussion.

Author information

Authors and Affiliations

  1. Department of Life Sciences (R&D), Datt Mediproducts Pvt. Ltd., Roz Ka Meo Industrial Area, Nuh, District Mewat, Haryana, 122103, India

    Anupama Kakkar, Ashima Sorout, Mahak Tiwari, Pallavi Shrivastava, Poonam Meena, Sumit Kumar Saraswat, Supriya Srivastava & Siddharth Pandey

  2. Datt Mediproducts Pvt Ltd., 56, Community Centre, East of Kailash, New Delhi, Delhi, 110065, India

    Rajan Datt

Authors
  1. Anupama Kakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashima Sorout
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahak Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pallavi Shrivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Poonam Meena
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sumit Kumar Saraswat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Supriya Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rajan Datt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Siddharth Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siddharth Pandey.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interests.

Ethical statement

There are no animal expreiments carried out for this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kakkar, A., Sorout, A., Tiwari, M. et al. Current Status of Stem Cell Treatment for Type I Diabetes Mellitus. Tissue Eng Regen Med 15, 699–709 (2018). https://doi.org/10.1007/s13770-018-0143-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13770-018-0143-9

Keywords

Search

Navigation